Lv1
92 积分 2024-10-02 加入
Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue
5小时前
待确认
Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor
7小时前
求助中
Unlocking the promise of RAS inhibition in pancreatic cancer
7小时前
已完结
Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras
10小时前
已完结
Abstract 6782: Discovery of a new class of mutant-targeted catalytic RAS(ON) inhibitors with retained antitumor activity in setting of emergent resistance due to elevated RAS flux
4天前
已完结
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
9天前
已完结
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
9天前
已完结
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
9天前
已完结
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
9天前
已完结
Safety assessment of antibody-drug conjugates: Nonclinical toxicology, non-active ingredients, and environmental risk considerations
17天前
已完结
皖公网安备34019202002308
